文献速递免疫规划卫生政策与健康促进

英国扩展重组带状疱疹疫苗年龄资格的流行病学效果与成本效果

The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England.
PubMed 文献 · Vaccine · 2026-03-04

该研究从英国国家卫生服务体系视角构建静态队列模型,评估将重组带状疱疹疫苗(RZV)扩展至80岁及以上人群的可行性与成本效果。结果显示,为80岁及以上人群提供单剂RZV相对现行程序可能具有成本效果,两剂成本效果较低但保护更强。

要点

  • 为80岁及以上人群提供单剂RZV相对现行程序可能具有成本效果
  • 为80岁及以上人群提供两剂RZV成本效果较低但保护作用更强
  • 预防健康相关生活质量损失以接种60-69岁人群最有效,避免住院费用以接种80-89岁人群最有效

核心结论

  • 将现行程序扩展至为80岁及以上人群提供单剂RZV相对现行程序可能具有成本效果。
  • 为80岁及以上人群提供两剂RZV成本效果较低,但可提供更大保护。
  • 为老年人提供一剂或两剂RZV可具有成本效果并减轻带状疱疹医疗负担。

研究设计与样本

  • 成本-效用分析,采用静态队列模型,从英国国家卫生服务体系视角开展。
  • 模型考虑带状疱疹病例、导致带状疱疹后神经痛的重症病例、带状疱疹相关住院和死亡。
  • 模型评估RZV长期影响,并纳入人口人口学变化及既往提供的减毒活带状疱疹疫苗(ZVL)。
  • 考虑聚焦80岁及以上老年人群的不同RZV资格情景,并与2023年前程序比较。

主要发现

  • 扩展当前程序为80岁及以上人群提供单剂RZV相对当前程序可能具有成本效果。
  • 为该人群提供两剂RZV成本效果较低但保护作用更大。
  • 预防健康相关生活质量损失以接种60-69岁人群最有效。
  • 避免住院费用以接种80-89岁人群最有效。

临床怎么用

  • 决策者可参考单剂RZV扩展至80岁及以上人群的成本效果评估结果。
  • 若优先考虑更大保护可考虑两剂方案,但需权衡成本效果。
  • 不同年龄优先接种策略在生活质量损失与住院费用避免上的效率不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Since September 2023, England's national immunisation programme has offered the recombinant zoster vaccine (RZV) to adults aged 65-79 as a preventative measure against shingles (herpes zoster) and its complications. However, adults aged 80 and over are currently not eligible for the vaccine. We aimed to evaluate the feasibility and cost-effectiveness of providing RZV to adults aged 80 and older in England. METHODS: This cost-utility analysis employs a static cohort model considering herpes zoster (HZ) cases and severe cases leading to post-herpetic neuralgia, HZ-related hospitalisation, and deaths from the perspective of the National Health Service. The long-term impacts of RZV are assessed using the model, accounting for changing population demographics and the previously-offered live zoster vaccine (ZVL). We consider different eligibility scenarios for RZV focusing on the older population (80+ years old) and provide comparisons to the pre-2023 programme. RESULTS: Expanding the current programme to offer a single dose of RZV to people aged 80 and up is likely to be cost-effective relative to the current programme. Offering two doses to this group would be less cost-effective but would offer greater protection against HZ. For preventing health-related quality of life loss, it is most efficient to vaccinate 60-69-year-olds, but for averting hospitalisation costs, it is most efficient to vaccinate 80-89-year-olds. CONCLUSION: Providing one or two doses of RZV for older adults can be cost-effective and would reduce the healthcare burden of shingles.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ku CC, Rosello A, Walker J, et al. The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England. Vaccine. 2026. PMID: 41785676. doi:10.1016/j.vaccine.2026.128405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。